RE:RE:RE:RE:I have a 40 page LABS research / valuation report available subaru1i wrote: I am impressed, just standing back as an observer, how Danny has better insights than the CEO of LABS. I'm really impressed, but carry on because no one knows how much market share the generic version of Epidiolex is going to take away from GW nor what the structure of the contract terms and conditions are between Medipharm Labs and their global pharma partner. If this was fishing, I'd have a bucket full of suckers already ;-)
im impressed by the assumptions you are making again
who is to say that all generic EPIOLEX will be made with plant derrived CBD the makers of the generic stuff may opt to go with the syntheticaly produced stuff for many different reasons im not going to get into (you can figure out the dis/advantages of either.
but here is a little science for you to read:
introduction: Cannabidiol (CBD) can be isolated from Cannabis sativa L. or synthetically produced. The aim of this study was to compare the in vitro effects of purified natural and synthetic CBD to establish any pharmacological differences or superiority between sources. Methods: Six purified samples of CBD were obtained, 4 of these were natural and 2 synthetic. The anticancer effects of CBD were assessed in a human ovarian cancer cell line (SKOV-3 cells). The neuroprotective effects of CBD were assessed in human pericytes in a model of stroke (oxygen glucose deprivation [OGD]). The ability of CBD to restore inflammation-induced intestinal permeability was assessed in differentiated human Caco-2 cells (a model of enterocytes). Results: (1) In proliferating and confluent SKOV-3 cells, all CBD samples similarly reduced resazurin metabolism as a marker of cell viability in a concentration-dependent manner (p < 0.001). (2) In pericytes exposed to OGD, all CBD samples similarly reduced cellular damage (measured by lactate dehydrogenase) at 24 h by 31–48% and reduced inflammation (measured by IL-6 secretion) by 30–53%. Attenuation of IL-6 was inhibited by 5HT1A receptor antagonism for all CBD sources. (3) In differentiated Caco-2 cells exposed to inflammation (TNFα and IFNγ, 10 ng/mL for 24 h), each CBD sample increased the speed of recovery of epithelial permeability compared to control (p < 0.05–0.001), which was inhibited by a CB1 receptor antagonist. Conclusion: Our results suggest that there is no pharmacological difference in vitro in the antiproliferative, anti-inflammatory, or permeability effects of purified natural versus synthetic CBD. The purity and reliability of CBD samples, as well as the ultimate pharmaceutical preparation, should all be considered above the starting source of CBD in the development of new CBD medicines. https://karger.com/mca/article/4/2/86/820122/The-Pharmacological-Effects-of-Plant-Derived